Clinical Trial Update: Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the safety and immunogenicity of GlaxoSmithKline's herpes zoster subunit vaccine in adults 18 and older with hematologic cancers; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• Shingrix (recombinant zoster vaccine, adjuvanted)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Herpes Zoster | Phase 3 | Status: COMPLETED | Results posted: 2017-05-25